Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension study achieving complete response or well-controlled disease. Safety profile remained favorable with low-frequency, predominantly low-grade adverse events. The company plans to initiate a Phase 2b study in the second half of 2026.

01/08/2026, 7:00 AM • GlobeNewswire

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating potential securities misconduct for Driven Brands and Jasper Therapeutics, alleging false statements about business performance and operational practices.

11/22/2025, 11:49 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm

Law firm reminds investors of class action lawsuits against multiple companies, alleging false or misleading statements about business operations, financial conditions, and prospects.

11/17/2025, 5:30 PM • GlobeNewswire

JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

Rosen Law Firm is notifying investors of a securities class action lawsuit against Therapeutics for allegedly making false or misleading statements about manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.

11/16/2025, 11:40 PM • GlobeNewswire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and potential regulatory issues during the period of November 30, 2023 to July 3, 2025.

11/10/2025, 12:00 PM • GlobeNewswire

JSPR IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

Rosen Law Firm alerts Jasper Therapeutics investors about a securities class action lawsuit regarding potential misleading statements about manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.

11/07/2025, 5:47 PM • GlobeNewswire

Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Jasper Therapeutics faces a class action lawsuit alleging securities fraud after revealing issues with a drug product lot that impacted clinical trial results, leading to study halts and significant stock price decline.

11/03/2025, 2:50 PM • GlobeNewswire

JSPR DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JSPR

Rosen Law Firm is pursuing a securities class action lawsuit against Therapeutics for allegedly making false and misleading statements about manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.

10/31/2025, 5:38 PM • GlobeNewswire

DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts shareholders about potential securities fraud class action lawsuits for multiple companies, with allegations of misleading statements and financial misrepresentations across different class periods.

10/31/2025, 12:00 PM • GlobeNewswire

JASPER CLASS ACTION: Bragar Eagel & Squire, P.C. Reminds Jasper Stockholders of the November 18th Deadline for Filed Class Action Lawsuit

A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and regulatory compliance during the period of November 30, 2023 to July 3, 2025.

10/29/2025, 5:49 PM • GlobeNewswire

Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Jasper Therapeutics faces potential securities fraud lawsuit after revealing issues with a drug product lot in clinical trials, leading to study halts and significant stock price decline.

10/27/2025, 12:00 PM • GlobeNewswire

JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Jasper Therapeutics Stockholders to Contact the Firm Regarding Filed Class Action

A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and potential regulatory and commercial risks.

10/25/2025, 1:08 PM • GlobeNewswire

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR

Rosen Law Firm alerts Jasper Therapeutics investors about a securities class action lawsuit alleging false statements regarding manufacturing controls and product prospects, with a lead plaintiff deadline of November 18, 2025.

10/25/2025, 12:33 PM • GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR

Rosen Law Firm alerts Jasper Therapeutics investors about a securities class action lawsuit alleging false statements regarding manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.

10/22/2025, 11:11 PM • GlobeNewswire

JSPR Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Jasper Therapeutics, Inc. Class Action

Jasper Therapeutics faces a class action lawsuit alleging misleading investors about product manufacturing controls and commercial prospects, resulting in a 55.1% stock price drop on July 7, 2025.

10/22/2025, 8:40 PM • GlobeNewswire